• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      FDA Cancer Division Head Defends Avastin Decision

      Posted Atblogs.wsj.com

      Defending Decision: The head of the FDA’s cancer-drug division defended the agency’s proposal to strip Genentech’s Avastin of its marketing approval for breast cancer, the WSJ reports. Richard Pazdur tells the paper that there were longtime issues with the trial Genentech says shows Avastin can delay tumor growth in advanced breast cancer patients, and that the cost of the drug wasn’t an issue. Studies have not shown that the drug prolongs actual survival in breast-cancer patients, and there is a risk of serious side effects, the FDA says.

      Budgeting Battle: Republicans are rejecting an estimate by the nonpartisan Congressional Budget Office that puts the cost of repealing the health-care overhaul law at $230 billion over ten years, the New York Times reports. House Speaker John Boehner says the CBO’s scoring of the health bill is based on incorrect assumptions and double-counting by the bill’s proponents.

      Mad About Medicaid: The health-care overhaul law includes the eventual expansion of Medicaid to cover 16 million lower-income Americans, but Republican governors are now asking the Obama administration to permit states to drop enrollees without losing federal funding, the WSJ reports. In a letter to be sent today, 33 GOP governors call the effect of the federal requirements “unconscionable,” the paper says.

      Insurance Inquiries: California’s brand-new insurance commissioner wants nonprofit insurer Blue Shield of California to hold off on some planned steep premium increases so he can analyze them, the Los Angeles Times reports. Blue Shield has said that the increases, which will amount to a total of 59% for some policyholders over a period of more than a year, have nothing to do with the health-care overhaul law but are a consequence of ongoing trends in the individual market.

      Jan 10, 2011


       

      Share this Article!

    Back to top^